Literature DB >> 19164345

Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB.

K Kliiman1, A Altraja.   

Abstract

Treatment outcome in multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) is often unsuccessful, but the particular determinants of poor treatment outcome have remained obscure. The present authors therefore analysed treatment effectiveness and predictors of poor treatment outcome in pulmonary MDR-TB and XDR-TB in Estonia, a European country with one of the highest MDR-TB and XDR-TB rates in the world. All culture-confirmed pulmonary MDR-TB and XDR-TB patients who started TB treatment in 2003-2005 were included. Multivariate analysis was performed on two models of predictors: 1) patients' HIV-status, demographic and socioeconomic characteristics; and 2) TB-related data. In the 235 MDR-TB patients, the proportion of overall successful treatment outcome was 60.4%, rising to 72.8% among adherent patients. Among the 54 XDR-TB patients, these proportions were 42.6% and 50.0%, respectively. Risk factors for poor treatment outcome in MDR-TB were HIV infection, previous TB treatment, resistance to ofloxacin and positive acid-fast bacilli (AFB) smear at the start of treatment. Predictors of poor treatment outcome in XDR-TB were urban residence and positive AFB smear. This country-wide study provides evidence that to improve treatment outcome in multidrug-resistant and extensively drug-resistant tuberculosis, special care should be taken to treat HIV-infected patients and urban residents, as well as to make efforts to diminish re-treatment cases by increasing patient adherence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164345     DOI: 10.1183/09031936.00155708

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  56 in total

Review 1.  Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.

Authors:  Karen R Jacobson; Dylan B Tierney; Christie Y Jeon; Carole D Mitnick; Megan B Murray
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

2.  Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates.

Authors:  Florence Brossier; Nicolas Veziris; Alexandra Aubry; Vincent Jarlier; Wladimir Sougakoff
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

3.  Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains.

Authors:  Florence Brossier; David Guindo; Anne Pham; Florence Reibel; Wladimir Sougakoff; Nicolas Veziris; Alexandra Aubry
Journal:  J Clin Microbiol       Date:  2016-04-06       Impact factor: 5.948

Review 4.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

5.  Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.

Authors:  Florence Brossier; Anne Pham; Christine Bernard; Alexandra Aubry; Vincent Jarlier; Nicolas Veziris; Wladimir Sougakoff
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

6.  Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.

Authors:  Aurélie Fillion; Alexandra Aubry; Florence Brossier; Aurélie Chauffour; Vincent Jarlier; Nicolas Veziris
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

7.  Microevolution of extensively drug-resistant tuberculosis in Russia.

Authors:  Nicola Casali; Vladyslav Nikolayevskyy; Yanina Balabanova; Olga Ignatyeva; Irina Kontsevaya; Simon R Harris; Stephen D Bentley; Julian Parkhill; Sergey Nejentsev; Sven E Hoffner; Rolf D Horstmann; Timothy Brown; Francis Drobniewski
Journal:  Genome Res       Date:  2012-01-31       Impact factor: 9.043

8.  Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation.

Authors:  A C Miller; I Y Gelmanova; S Keshavjee; S Atwood; G Yanova; S Mishustin; J J Furin; S S Shin
Journal:  Int J Tuberc Lung Dis       Date:  2012-04-09       Impact factor: 2.373

9.  A close-up on the epidemiology and transmission of multidrug-resistant tuberculosis in Poland.

Authors:  T Jagielski; A Brzostek; A van Belkum; J Dziadek; E Augustynowicz-Kopeć; Z Zwolska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-20       Impact factor: 3.267

10.  Tuberculosis treatment adherence and fatality in Spain.

Authors:  Joan A Caylà; Teresa Rodrigo; Juan Ruiz-Manzano; José A Caminero; Rafael Vidal; José M García; Rafael Blanquer; Martí Casals
Journal:  Respir Res       Date:  2009-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.